ScholarLens Back to search
2010•Qilu yixue zazhiRequires access

FLUDARABINE,CYTARABINE AND G-CSF REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID LEUKAEMIA

Z Wang

Open publisher page 0 citations

Abstract

Objective To evaluate combo therapy with fludarabine, cytarabine, and G-CSF (FLAG) for relapsed and refractory acute myeloid leukaemia (AML). Methods The combo therapy of FLAG was applied in the treatment of 20 patients with relapsed and refractory AML. Results Eight (40%) patients achieved complete remission (CR), and four (20%) partial remission, non-remission five, and death three, the effective power being 60%. The main side effects were gastrointestinal tract reactions and bone marrow depression. Conclusion FLAG therapy is effective for relapsed and refractory acute myeloid leukaemia.

About this research paper

What this paper is about

Objective To evaluate combo therapy with fludarabine, cytarabine, and G-CSF (FLAG) for relapsed and refractory acute myeloid leukaemia (AML). Methods The combo therapy of FLAG was applied in the treatment of 20 patients with relapsed and refractory AML. Results Eight (40%) patients achieved complete remission (CR), and four (20%) partial remission, non-remission five, and death three, the effective power being 60%. The main side effects were gastrointestinal tract reactions and bone marrow depression. Conclusion FLAG therapy is effective for relapsed and refractory acute myeloid leukaemia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate combo therapy with fludarabine, cytarabine, and G-CSF (FLAG) for relapsed and refractory acute myeloid leukaemia (AML). Methods The combo therapy of FLAG was applied in the treatment of 20 patients with relapsed and refractory AML. Results Eight (40%) patients achieved complete remission (CR), and four (20%) partial remission, non-remission five, and death three, the effective power being 60%. The main side effects were gastrointestinal tract reactions and bone marrow depression. Conclusion FLAG therapy is effective for relapsed and refractory acute myeloid leukaemia.

Key concepts: Medicine, Flag (linear algebra), Cytarabine, Refractory (planetary science), Fludarabine, Internal medicine, Regimen, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
FLUDARABINE,CYTARABINE AND G-CSF REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID LEUKAEMIA — Research Paper | ScholarLens